Clinical Trials

147 enrolled

Leukemia, Myeloid, Acute

NCT05564390 2026-05-26

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

2,000 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT02115295 2026-05-20

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

508 enrolled

Blast Crisis, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT06222580 2026-05-14

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

30 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT03182244 2026-05-05

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

276 enrolled 41 charts

Leukemia, Myeloid, Acute

NCT04293562 2026-05-05

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Phase 3 Recruiting

1,186 enrolled

Leukemia, Myeloid, Acute

NCT07140016 2026-05-01

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05955261 2026-04-23

A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

Phase 2 Suspended

70 enrolled

Leukemia, Myeloid, Acute

NCT07548710 2026-04-23

Study of SA+X in the Treatment of Newly Diagnosed AML

205 enrolled

Leukemia, Myeloid, Acute

NCT04140487 2026-04-16

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

97 enrolled

Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT07032727 2026-04-15

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

68 enrolled

Targeted Therapy

NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

171 enrolled

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT05756777 2026-03-27

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

18 enrolled

Phase 3 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07407140 2026-03-25

VAG-3+7-G

300 enrolled

Leukemia, Myeloid, Acute

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07463651 2026-03-20

TROPHY-15

Phase 3 Recruiting

594 enrolled

Phase 1/2 Active not recruiting

Leukemia, Myeloid, Acute

NCT05520567 2026-03-04

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

70 enrolled

Phase 2/3 Not yet recruiting

Neoplasms, Leukemia, Myeloid, Acute

NCT07425808 2026-02-23

FIT-AML

230 enrolled

Leukemia, Myeloid, Acute

NCT05010122 2026-02-18

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

42 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05010772 2026-01-14

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

125 enrolled

Leukemia, Myeloid, Acute

NCT04240002 2026-01-05

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

9 enrolled 21 charts

371 enrolled 36 charts 2 FDA

Leukemia, Myeloid, Acute

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Phase 3 Completed

Leukemia, Myeloid, Acute

NCT06235801 2025-11-19

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

20 enrolled

Leukemia, Myeloid

NCT06225427 2025-10-20

Gilteritinib for the Treatment of ALK NSCLC

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02752035 2025-09-12

A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Phase 3 Completed

183 enrolled 30 charts

Leukemia, Myeloid, Acute

NCT06734585 2025-09-12

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Completed

114 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT02310321 2025-09-02

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

97 enrolled 30 charts

Leukemia, Myeloid, Acute

NCT07131059 2025-08-20

MRD-positive AML Clinical Study

Phase NA Recruiting

120 enrolled

Phase NA Not yet recruiting

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06992934 2025-08-03

TARGETALLO

10 enrolled

Phase 2 Active not recruiting

Hematologic Neoplasms

NCT03836209 2025-06-15

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

181 enrolled 18 charts

Leukemia, Myeloid, Acute

NCT04691648 2025-05-31

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Completed

33 enrolled

Recurrence, Leukemia, Myeloid, Acute

NCT06696183 2025-05-29

SEQUENCE

60 enrolled

Leukemia, Myeloid, Acute

NCT06022003 2025-03-24

OGILAR

33 enrolled

Phase 2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT06667973 2025-03-12

Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid Leukemia

80 enrolled

Disease, Leukemia, Myeloid, Acute

NCT02997202 2025-01-17

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Phase 3 Completed

356 enrolled 22 charts

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT04027309 2024-12-17

HOVON 156 AML

777 enrolled

Leukemia, Myeloid, Acute

NCT02014558 2024-12-03

Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

265 enrolled 80 charts

Leukemia, Myeloid, Acute

NCT03730012 2024-11-29

A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML)

11 enrolled 18 charts

Leukemia, Myeloid, Acute

NCT02495233 2024-11-27

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Phase 1/2 Terminated

10 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02927262 2024-11-26

A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Phase 2 Completed

98 enrolled 17 charts

Leukemia, Myeloid, Acute

NCT02561455 2024-11-19

Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial

9 enrolled 13 charts

Leukemia, Myeloid, Acute

NCT02181660 2024-11-06

Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1 Completed

24 enrolled

Leukemia, Myeloid, Acute

NCT02236013 2024-11-05

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 1 Completed

80 enrolled

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT02456883 2024-11-05

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Phase 1 Completed

6 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT05177731 2024-10-03

Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML

188 enrolled

Leukemia, Myeloid, Acute

NCT06221683 2024-08-22

GMCAII

500 enrolled

Leukemia, Myeloid, Acute

NCT05028751 2024-08-07

A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

Phase 1/2 Terminated

24 enrolled 19 charts

Leukemia, Myeloid, Acute

NCT05546580 2024-07-29

FRIDA

50 enrolled

Leukemia, Myeloid, Acute

NCT04336982 2024-05-31

A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia

Phase 1 Terminated

22 enrolled

Leukemia, Leukemia, Myeloid, Acute

NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

Phase 1 Withdrawn